A Phase 2 Study of Bevacizumab in Combination with Carboplatin and Paclitaxel in Patients with Non-Squamous Non-Small-Cell Lung Cancer harboring Mutations of EGFR after failing First-line EGFR-TKIs

Phase 2

• Conditions: on-squamous Non-small-cell Lung Cancer

• Registration Number: JPRN-UMIN000003263
• Lead Sponsor: Hanshin Cancer Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-02-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1)Interstitial pneumonia or pulmonary fibrosis detectable on CT scan 2)History of drug induced interstitial pneumonia 3)History of severe drug allergy 4)History of active infection or other serious disease condition (GI bleeding,etc.) 5)History of poorly controlled pleural effusion,pericardial effusion and ascites 6)History of severe heart disease(uncontrollable arrythmia,uncontrollable angina pectoris,herat failure,etc.) 7)Uncontrollable hypertension 8)Uncontrollable diabetes mellitus 9)Current or previous history of hemoptysis or hemosputum 10)Current or previous (within the last 1 year) history of cerebrovascular disease 11)Current or previous (within the last 1 year) history of GI perforation 12)Symptomatic brain metastasis 13)Traumatic fracture of unrecovery 14)The operation has been scheduled for the examination period 15)Tumor invasive to the chest large blood vessel. Cavity in brain or lung tumor. 16)Evidence of bleeding diathesis or coagulopathy 17)Thrombosis that need to treat 18)History of active double cancer 19)History of active psychological disease 20)History of pregnancy or lactation

Study & Design

• Study Type: Interventional
• Study Design: Not specified